ID

12971

Descripción

A Safety Study Comparing Natrecor (Nesiritide) Versus Dobutamine Therapy for Worsening Congestive Heart Failure; ODM derived from: https://clinicaltrials.gov/show/NCT00270400

Link

https://clinicaltrials.gov/show/NCT00270400

Palabras clave

Versiones (1)
  1. 8/1/16 8/1/16 -
Titular de derechos de autor

CC BY-NC 3.0

Subido en

8 de enero de 2016

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY-NC 3.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Heart Failure, Congestive NCT00270400

Inglés

Eligibility Heart Failure, Congestive NCT00270400

1 formularios  
Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
history of nyha (new york heart association) class iii or iv congestive heart failure (chf)
Descripción

congestive heart failure

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1275491
has symptomatic, decompensated chf for which inpatient therapy with either dobutamine or natrecor®, administered as a single intravenous vasoactive agent (drugs that influence the tone and caliber of blood vessels) with or without diuretics, is deemed appropriate
Descripción

has symptomatic, decompensated chf for which inpatient therapy with either dobutamine or natrecor®, administered as a single intravenous vasoactive agent (drugs that influence the tone and caliber of blood vessels) with or without diuretics, is deemed appropriate

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0018802
UMLS CUI [2]
C0012963
UMLS CUI [3]
C0012798
receiving stable doses of oral antiarrhythmic medications (medications that help regulate irregular heart beats) for at least the 48 hours before starting study drug, or receiving no antiarrhythmic medications.
Descripción

oral antiarrhythmic medications

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0003195
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
cannot tolerate a 24-hour baseline holter monitoring period without intravenous vasoactive medications, and/or cannot tolerate the specified washout period (if applicable) of intravenous vasoactive medications before starting the baseline holter monitoring
Descripción

cannot tolerate a 24-hour baseline holter monitoring period without intravenous vasoactive medications, and/or cannot tolerate the specified washout period (if applicable) of intravenous vasoactive medications before starting the baseline holter monitoring

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1980011
has systolic blood pressure consistently < 85 mm hg, cardiogenic shock, or other evidence of significant hemodynamic instability requiring the immediate institution of inotropic/pressor support
Descripción

has systolic blood pressure consistently < 85 mm hg, cardiogenic shock, or other evidence of significant hemodynamic instability requiring the immediate institution of inotropic/pressor support

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0005823
UMLS CUI [2]
C0036980
UMLS CUI [3]
C0948268
has a clinical condition expected to require therapy with more than one intravenous vasoactive agent or dopamine during the 24-hour treatment holter monitoring period
Descripción

has a clinical condition expected to require therapy with more than one intravenous vasoactive agent or dopamine during the 24-hour treatment holter monitoring period

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1980011
UMLS CUI [2]
C0013030
has received treatment with dopamine or any intravenous vasoactive medication such as dobutamine, milrinone, nitroprusside or intravenous nitroglycerin for more than 4 hours for the current episode of decompensated chf or related illness
Descripción

has received treatment with dopamine or any intravenous vasoactive medication such as dobutamine, milrinone, nitroprusside or intravenous nitroglycerin for more than 4 hours for the current episode of decompensated chf or related illness

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0013030
UMLS CUI [2]
C0012963
UMLS CUI [3]
C0128513
UMLS CUI [4]
C0028193
UMLS CUI [5]
C0017887
requires an intravenous antiarrhythmic medication during the 48 hours before starting the study
Descripción

requires an intravenous antiarrhythmic medication during the 48 hours before starting the study

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0003195
Volver a la parte superior de la página

Similar models

Eligibility Heart Failure, Congestive NCT00270400

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
congestive heart failure
Item
history of nyha (new york heart association) class iii or iv congestive heart failure (chf)
boolean
C1275491 (UMLS CUI [1])
has symptomatic, decompensated chf for which inpatient therapy with either dobutamine or natrecor®, administered as a single intravenous vasoactive agent (drugs that influence the tone and caliber of blood vessels) with or without diuretics, is deemed appropriate
Item
has symptomatic, decompensated chf for which inpatient therapy with either dobutamine or natrecor®, administered as a single intravenous vasoactive agent (drugs that influence the tone and caliber of blood vessels) with or without diuretics, is deemed appropriate
boolean
C0018802 (UMLS CUI [1])
C0012963 (UMLS CUI [2])
C0012798 (UMLS CUI [3])
oral antiarrhythmic medications
Item
receiving stable doses of oral antiarrhythmic medications (medications that help regulate irregular heart beats) for at least the 48 hours before starting study drug, or receiving no antiarrhythmic medications.
boolean
C0003195 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
cannot tolerate a 24-hour baseline holter monitoring period without intravenous vasoactive medications, and/or cannot tolerate the specified washout period (if applicable) of intravenous vasoactive medications before starting the baseline holter monitoring
Item
cannot tolerate a 24-hour baseline holter monitoring period without intravenous vasoactive medications, and/or cannot tolerate the specified washout period (if applicable) of intravenous vasoactive medications before starting the baseline holter monitoring
boolean
C1980011 (UMLS CUI [1])
has systolic blood pressure consistently < 85 mm hg, cardiogenic shock, or other evidence of significant hemodynamic instability requiring the immediate institution of inotropic/pressor support
Item
has systolic blood pressure consistently < 85 mm hg, cardiogenic shock, or other evidence of significant hemodynamic instability requiring the immediate institution of inotropic/pressor support
boolean
C0005823 (UMLS CUI [1])
C0036980 (UMLS CUI [2])
C0948268 (UMLS CUI [3])
has a clinical condition expected to require therapy with more than one intravenous vasoactive agent or dopamine during the 24-hour treatment holter monitoring period
Item
has a clinical condition expected to require therapy with more than one intravenous vasoactive agent or dopamine during the 24-hour treatment holter monitoring period
boolean
C1980011 (UMLS CUI [1])
C0013030 (UMLS CUI [2])
has received treatment with dopamine or any intravenous vasoactive medication such as dobutamine, milrinone, nitroprusside or intravenous nitroglycerin for more than 4 hours for the current episode of decompensated chf or related illness
Item
has received treatment with dopamine or any intravenous vasoactive medication such as dobutamine, milrinone, nitroprusside or intravenous nitroglycerin for more than 4 hours for the current episode of decompensated chf or related illness
boolean
C0013030 (UMLS CUI [1])
C0012963 (UMLS CUI [2])
C0128513 (UMLS CUI [3])
C0028193 (UMLS CUI [4])
C0017887 (UMLS CUI [5])
requires an intravenous antiarrhythmic medication during the 48 hours before starting the study
Item
requires an intravenous antiarrhythmic medication during the 48 hours before starting the study
boolean
C0003195 (UMLS CUI [1])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial